Patent classifications
C07D279/14
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
The present invention is directed to compounds of Formula I:
##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
The present invention is directed to compounds of Formula I:
##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
THERAPEUTIC COMPOUNDS
The invention provides compounds having the general formula I:
##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
THERAPEUTIC COMPOUNDS
The invention provides compounds having the general formula I:
##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
[6,6] fused bicyclic HDAC8 inhibitors
The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein, useful as inhibitors of zinc-dependent histone deacetylases (HDACs) and in the treatment of diseases or disorders associated with HDACs.
[6,6] fused bicyclic HDAC8 inhibitors
The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein, useful as inhibitors of zinc-dependent histone deacetylases (HDACs) and in the treatment of diseases or disorders associated with HDACs.
Therapeutic compounds
The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscipt m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Therapeutic compounds
The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscipt m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
SMALL MOLECULE PROTEASOME ACTIVATORS AND USES THEREOF
The disclosure is directed to compounds of the formula (I) and (II) and uses of such compounds to treat, among other conditions, neurodegenerative diseases and cancers.
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
The present invention is directed to compounds of Formula I:
##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.